Related Experiment Videos
CBP and p300: HATs for different occasions
1Department of Metabolic and Endocrine Diseases, UMC Utrecht, Lundlaan 6, 3584 EA, The Netherlands. e.kalkhoven@azu.nl
Biochemical Pharmacology
|August 18, 2004
Summary
CREB binding protein (CBP) and p300 are crucial transcriptional coactivators. Their distinct roles in acetylation are vital for biological processes and understanding their regulation may lead to new therapeutic strategies for human diseases.
Area of Science:
- Molecular Biology
- Epigenetics
- Biochemistry
Background:
- CREB binding protein (CBP) and p300 are key transcriptional coactivators regulating RNA polymerase II.
- Genetic alterations and functional inactivation of CBP and p300 are linked to human diseases.
- These proteins' ability to acetylate histones and other proteins is critical for numerous biological processes.
Purpose of the Study:
- To explore the unique roles of CBP and p300 beyond their homology.
- To investigate the mechanisms behind their differential protein associations and substrate specificities.
- To understand how regulating CBP and p300 activity can inform therapeutic strategies for associated diseases.
Main Methods:
- Analysis of findings from patients with genetic alterations.
- Studies using knockout mouse models.
- Cell-based experimental systems to inactivate acetyltransferase function.
Main Results:
- Evidence suggests CBP and p300 are not fully redundant and possess unique in vivo functions.
- Functional differences may arise from distinct protein interactions or substrate specificities.
- Inactivation studies are crucial for elucidating specific biological roles.
Conclusions:
- Understanding the specific biological roles of CBP and p300 through functional inactivation is essential.
- Elucidating the regulatory mechanisms of CBP and p300 in vivo is key for developing novel therapeutic strategies.
- CBP and p300 are critical targets for therapeutic interventions in a wide range of human diseases.